We are monitoring the impact of COVID-19 on APAC Solid Tumor Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 6309
Share on
Share on

APAC Solid Tumor Market Research Report – Segmented By Disease, Drugs and Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) - Industry Analysis, Size, Share, Growth, Trends and Forecast (2021 to 2026)

Pulished: April, 2021
ID: 6309
Pages: 145

APAC Solid Tumor Market (2021 to 2026)

The Solid Tumor Market in the Asia Pacific is projected to rise at a promising CAGR during the forecast period.

Solid tumors are formed due to the collection of abnormal tissues that do not contain any cyst or liquid regions within. Solid tumors are of two types, i.e., benign (non-cancerous) and malignant (cancerous) in nature.

Some of the significant driving agents for this market's growth include increasing incidences of several cases of solid tumors. Due to an increase in the number of cases, there has been an increasing demand for highly effective chemotherapeutic agents, which drives the market. 

The high expense of cancer therapy, an increase in drug patent cliff, and the increasing size of non-proprietary therapeutic products are anticipated to be the growth hindering factors for the APAC Solid Tumor therapeutics market.

This research report has been segmented and sub-segmented into the following categories:

By Disease:

  • Breast cancer     
  • Lung cancer      
  • Colorectal cancer
  • Prostate cancer
  • Cervical cancer
  • Others    

By Drugs:

  • Carboplatin       
  • Cisplatin  
  • Gemcitabine      
  • Paclitaxel
  • Doxorubicin      
  • Bevacizumab     
  • Erlotinib  
  • Sunitinib  
  • Everolimus      
  • Docetaxel       
  • Abiraterone     
  • Abiraterone acetate     
  • Cabazitaxel

By Country:

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

Regionally, Asia Pacific is a lucrative market and is expected to grow at a high CAGR during the forecast timeline. The Asia Pacific is the most lucrative market for the Solid Tumor market due to recent healthcare infrastructure improvements and expanding medical tourism in these regions. The region also accounts for a high cancer patient population, and increasing awareness and affordability of this region's people will contribute heavily towards the future growth of the market in the area.

With the Chinese government's hopeful plans for healthcare improvements, access to healthcare amenities and drugs is anticipated to grow in the coming decade, which could be a vital driver for the solid tumors market. However, pricing control in China and India could limit potential growth. In recent years, many efforts were made by the pricing and regulatory bodies in India and China to improve innovative drugs' access and affordability.

Major companies operating in the Asia Pacific Solid Tumor Market profiled in this report are Baxter International, Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, AstraZeneca plc, Abbott Laboratories, Inc., Amgen, Inc., Biogen Idec, Inc., Boehringer Ingelheim GmbH, Johnson & Johnson, GlaxoSmithKline plc, Kyowa Hakko Kirin Co., Ltd., and Sanofi among others.

Recent Market Developments:

  • On June 02, 2019, Roche made a public statement that the combination of Tecentriq, Avastin, carboplatin, and paclitaxel showed positive results in the patients suffering from liver metastases.
  • On December 02, 2019, two major companies, Innovent and Eli Lilly and Company, collectively launched their Tyvyt. The medicine works to restore the patient's tumor T-cell response. The result between the two companies provides patients with effective and protected treatment solution to fight against cancer.

1. Introduction                                

               1.1 Market Definition                    

               1.2 Study Deliverables                   

               1.3 Base Currency, Base Year and Forecast Periods                           

               1.4 General Study Assumptions                  

2. Research Methodology                                          

               2.1 Introduction               

               2.2 Research Phases                      

                              2.2.1 Secondary Research            

                              2.2.2 Primary Research  

                              2.2.3 Econometric Modelling      

                              2.2.4 Expert Validation   

               2.3 Analysis Design                         

               2.4 Study Timeline                          

3. Overview                                     

               3.1 Executive Summary                 

               3.2 Key Inferences                          

               3.3 Epidemology                             

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                        

               4.1 Market Drivers                         

               4.2 Market Restraints                    

               4.3 Key Challenges                         

               4.4 Current Opportunities in the Market                 

5. Market Segmentation                              

               5.1 Disease                       

                              5.1.1 Introduction           

                              5.1.2 Breast cancer         

                              5.1.3 Lung cancer            

                              5.1.4 Colorectal cancer  

                              5.1.5 Prostate cancer     

                              5.1.6 Cervical cancer      

                              5.1.7 Others       

                              5.1.8  Y-o-Y Growth Analysis, By disease 

                              5.1.9  Market Attractiveness Analysis, By disease 

                              5.1.10  Market Share Analysis, By disease

               5.2 Drugs                           

                              5.2.1 Introduction           

                              5.2.2 Carboplatin             

                              5.2.3 Cisplatin   

                              5.2.4 Gemcitabine           

                              5.2.5 Paclitaxel 

                              5.2.6 Doxorubicin            

                              5.2.7 Bevacizumab          

                              5.2.8 Erlotinib    

                              5.2.9 Sunitinib   

                              5.2.10 Everolimus            

                              5.2.11 Docetaxel             

                              5.2.12 Abiraterone          

                              5.2.13 Abiraterone acetate          

                              5.2.14 Cabazitaxel           

                              5.2.15 Y-o-Y Growth Analysis, By Drugs   

                              5.2.16 Market Attractiveness Analysis, By drugs   

                              5.2.17 Market Share Analysis, By drugs    

6. Geographical Analysis                              

               6.1 Introduction               

                              6.1.1 Regional Trends     

                              6.1.2 Impact Analysis      

                              6.1.3 Y-o-Y Growth Analysis         

                                             6.1.3.1 By Geographical Area

                                             6.1.3.2 By disease

                                             6.1.3.3 By drugs

                              6.1.4  Market Attractiveness Analysis       

                                             6.1.4.1 By Geographical Area

                                             6.1.4.2 By disease

                                             6.1.4.3 By drugs

                              6.1.5  Market Share Analysis        

                                             6.1.5.1 By Geographical Area

                                             6.1.5.2 By disease

                                             6.1.5.3 By drugs

               6.2 China                           

               6.3 India                            

               6.4 Japan                           

               6.5 South Korea               

               6.6 Australia                     

7. Strategic Analysis                                      

               7.1 PESTLE analysis                        

                              7.1.1 Political    

                              7.1.2 Economic 

                              7.1.3 Social        

                              7.1.4 Technological        

                              7.1.5 Legal         

                              7.1.6 Environmental       

               7.2 Porter’s Five analysis              

                              7.2.1 Bargaining Power of Suppliers         

                              7.2.2 Bargaining Power of Consumers     

                              7.2.3 Threat of New Entrants      

                              7.2.4 Threat of Substitute Products and Services  

                              7.2.5 Competitive Rivalry within the Industry        

8. Market Leaders' Analysis                                        

               8.1 Abbott Laboratories                

                              8.1.1 Overview  

                              8.1.2 Product Analysis    

                              8.1.3 Financial analysis   

                              8.1.4 Recent Developments         

                              8.1.5 SWOT analysis       

                              8.1.6 Analyst View           

               8.2 Boehringer Ingelheim GmbH                

               8.3 Baxter International                

               8.4 Bristol-Myers Squibb Company                           

               8.5 F. Hoffmann-La Roche Ltd.                  

               8.6 Eli Lilly and Company                             

               8.7 Johnson & Johnson                 

               8.8 GlaxoSmithKline plc                 

               8.9 Kyowa Hakko Kirin Co., Ltd.                 

               8.10 Sanofi                        

9. Competitive Landscape                                          

               9.1 Market share analysis                            

               9.2 Merger and Acquisition Analysis                         

               9.3 Agreements, collaborations and Joint Ventures                           

               9.4 New Product Launches                          

10. Market Outlook and Investment Opportunities                                           

Appendix                                          

               a) List of Tables                

               b) List of Figures              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms Disease and Drug along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Asia Pacific Solid Tumor Market, By Disease, From 2021 to 2026 (USD Million)
  2. Asia Pacific Breast cancer Market, By Region, From 2021 to 2026 (USD Million)
  3. Asia Pacific Lung cancer Market, By Region, From 2021 to 2026 (USD Million)
  4. Asia Pacific Liver cancer Market, By Region, From 2021 to 2026 (USD Million)
  5. Asia Pacific Colorectal cancer Market, By Region, From 2021 to 2026 (USD Million)
  6. Asia Pacific Cervical cancer Market, By Region, From 2021 to 2026 (USD Million)
  7. Asia Pacific Prostate cancer Market, By Region, From 2021 to 2026 (USD Million)
  8. Asia Pacific Others Market, By Region, From 2021 to 2026 (USD Million)
  9. Asia Pacific Solid Tumor Market, By Drugs, From 2021 to 2026 (USD Million)
  10. Asia Pacific Carboplatin Market, By Region, From 2021 to 2026 (USD Million)
  11. Asia Pacific Cisplatin Market, By Region, From 2021 to 2026 (USD Million)
  12. Asia Pacific Doxorubicin Market, By Region, From 2021 to 2026 (USD Million)
  13. Asia Pacific Paclitaxel Market, By Region, From 2021 to 2026 (USD Million)
  14. Asia Pacific Erlotinib Market, By Region, From 2021 to 2026 (USD Million)
  15. Asia Pacific Suntinib Market, By Region, From 2021 to 2026 (USD Million)
  16. Asia Pacific Everolimus Market, By Region, From 2021 to 2026 (USD Million)
  17. Asia Pacific Docetaxel Market, By Region, From 2021 to 2026 (USD Million)
  18. Asia Pacific Abiraterone acetate Market, By Region, From 2021 to 2026 (USD Million)
  19. Asia Pacific Others Market, By Region, From 2021 to 2026 (USD Million)
  20. Japan Solid Tumor Market, By Disease, From 2021 to 2026 (USD Million)
  21. Japan Solid Tumor Market, By Drugs, From 2021 to 2026 (USD Million)
  22. China Solid Tumor Market, By Disease, From 2021 to 2026 (USD Million)
  23. China Solid Tumor Market, By Drugs, From 2021 to 2026 (USD Million)
  24. India Solid Tumor Market, By Disease, From 2021 to 2026 (USD Million)
  25. India Solid Tumor Market, By Drugs, From 2021 to 2026 (USD Million)
  26. Australia Solid Tumor Market, By Disease, From 2021 to 2026 (USD Million)
  27. Australia Solid Tumor Market, By Drugs, From 2021 to 2026 (USD Million)
  28. South Korea Solid Tumor Market, By Disease, From 2021 to 2026 (USD Million)
  29. South Korea Solid Tumor Market, By Drugs, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample